-- 在Capital Power (CPX.TO)週三公佈第一季業績後，加拿大帝國商業銀行資本市場(CIBC Capital Markets)重申了對該公司股票的「跑贏大盤」評級，同時將目標股價從82加元下調至80加元。 CIBC認為，Capital Power業績公佈後股價的疲軟並不合理，可能反映出投資人對該公司能否帶來利多因素缺乏耐心。 CIBC表示：“然而，我們對CPX的中期增長前景仍然充滿信心。我們相信，隨著阿爾伯塔省和PJM的政策更加明朗，現有資產（以及未來投資）的增值潛力將得以實現。” CIBC指出，資料中心和阿爾伯塔省二期工程的進展，以及美國經濟成長的進展，都可能成為推動股價上漲的催化劑。 CIBC認為，股價疲軟反而是買進良機。
Price: $65.62, Change: $+3.25, Percent Change: +5.20%
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%